Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05942625
PHASE1

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Sponsor: Hansoh BioMedical R&D Company

View on ClinicalTrials.gov

Summary

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2023-05-23

Completion Date

2024-12-30

Last Updated

2024-10-09

Healthy Volunteers

Yes

Interventions

DRUG

HS-10390 tablet

Oral administration of specified dose of HS-10390

DRUG

Placebo tablet

Oral administration of matching dose ofplacebo

Locations (1)

Zhongda Hospital, Affiliated to Southeast University

Nanjing, Jiangsu, China